SCHEMBL25848811

SCHEMBL25848811

CC(C)c1ccc(CNC(=O)c2ccc(S(C)(=O)=O)s2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.51
RAB9A P51151 3/20 0.51
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
ALDH1A1 P00352 3/20 0.48
NPC1 O15118 2/20 0.48
NR2F2 P24468 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.43
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA7 P43166 1/20 0.43
HDAC3 O15379 3/20 0.42
HDAC1 Q13547 3/20 0.42
HDAC4 P56524 2/20 0.42
HDAC6 Q9UBN7 2/20 0.42
KDM4E B2RXH2 1/20 0.42
AKR1C3 P42330 1/20 0.40
EPHX2 P34913 1/20 0.40
NR1H4 Q96RI1 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25848866 0.90 HDAC3 (0.43) SMN1; SMN2RAB9AMEN1KMT2AALDH1A1
SCHEMBL24196149 0.89 HDAC3 (0.44) SMN1; SMN2RAB9AMEN1KMT2AALDH1A1
SCHEMBL25848782 0.88 KMT2A (0.49) SMN1; SMN2RAB9AMEN1KMT2AALDH1A1
SCHEMBL25848839 0.85 ALDH1A1 (0.49) SMN1; SMN2MEN1KMT2AALDH1A1HDAC3
SCHEMBL24196383 0.85 EPHX2 (0.42) SMN1; SMN2RAB9AMEN1KMT2AALDH1A1
SCHEMBL25848807 0.84 NR1H4 (0.52) RAB9AALDH1A1NPC1HDAC3HDAC1
SCHEMBL25848823 0.82 EPHX2 (0.61) RAB9AMEN1KMT2ANPC1L3MBTL1
SCHEMBL25848940 0.81 LSS (0.50) HDAC3HDAC1HDAC4HDAC6EPHX2
SCHEMBL25848826 0.80 USP5 (0.47) ALDH1A1HDAC3HDAC1HDAC4HDAC6
SCHEMBL25848829 0.79 HDAC3 (0.40) KMT2AALDH1A1HDAC3HDAC1HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219921-A1 KCNT1 INHIBITORS AND METHODS OF USE PRAXIS PRECISION MEDICINES, INC. 2023-07-13 US disclosed
US-20230219921-A1 KCNT1 INHIBITORS AND METHODS OF USE PRAXIS PRECISION MEDICINES, INC. 2023-07-13 US disclosed
EP-4175624-A1 KCNT1 INHIBITORS AND METHODS OF USE Praxis Precision Medicines, Inc. (US) 2023-05-10 EP disclosed
CN-116075297-A KCNT1 inhibitors and methods of use 普拉西斯精密医药公司 2023-05-05 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219921-A1 KCNT1 INHIBITORS AND METHODS OF USE KCNT1, KCNT2, KCNQ2 SMN1; SMN2 423/4885RAB9A 1720/4885MEN1 1117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.